

9373 Towne Centre Drive Suite 250 San Diego, CA 92121 (858)-552-2200 (858)-552-1936

FACSIMILE TRANSMISSION

DATE:

March 17, 2003

TO:

Examiner Liu, S. Group 1653

COMPANY: United States Patent Office

FAX NO.:

703-872-9306

FROM:

Amylin Pharmaceuticals, Inc.

RE:

U.S. Serial No. 09/889,330 Attorney Docket No. 030639.0027.UTL1

Number of pages being transmitted (including this cover sheet): 4

OFFICIAL

FAX RECEIVED

MAR 1 9 2003

GROUP 1600

ATTACHMENT:

- Transmittal
- Revocation of Prior Power of Attorney, Appointment of New Attorneys of Record and
- Change of Correspondence Address

This facsimile and the information it contains are intended to be a confidential communication only to the person or entity to whom it is addressed. If you have received this facsimile in error, please notify us by telephone and return the original fax to this office by mail.

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Young et al.

Art Unit:

1653

Appln. No.: 09/889,330

Examiner:

Liu. S.

Filed:

January 14, 2000

Atty. Docket: 030639.0027.UTL1

For:

NOVEL EXENDIN

FORMULATIONS AND

METHODS OF ADMINISTRATION

THEREOF

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL

Dear Sir:

Enclosed herewith for filing in the above-identified application is the following document:

 Revocation of Prior Power of Attorney, Appointment of New Attorneys of Record and Change of Correspondence Address

The Commissioner is authorized to charge any fees associated with the present submission to Deposit Account No. 010535.

Respectfully Submitted.

AMYLIN PHARMACEUTICALS, INC.

Date: 3/17/03

Molly A. Holman, Rh.D. Reg. No. 40,022

AMYLIN PHARMACEUTICALS, INC.

9373 Towne Centre Drive San Diego, California 92121 Telephone: (858) 552-2200 Facsimile: (858) 552-1936

> CERTIFICATE OF TRANSMISSION (37 C.F.R. 61.8)

eby certify that this paper is being transmitted to the United States Patent and Trademark Office on the date shown below via facsimile

March 17,2003

Vice Jus

Received from < 858-552-2212 > at 3/17/03 1:06:30 PM [Eastern Standard Time]

Appln. No. 09/889,330 Atty. Docket: 030639.0027.UTL1 Page 2

Matthew N. Bathon, Reg. No. 51,441 Timothy C. Bickham, Reg. No. 41,618 Scott A. Chambers, Reg. No. 37,573 Jay Chawla, Reg. No. 44,073 June E. Cohan, Reg. No. 43,741 Danielle M. Edwards, Reg. No. 51,645 James R. Farrand, Reg. No. 83,136 Joel M. Freed, Reg. No. 25,101 Dawn M. Gardner, Reg. No. 44,118 Barry Herman, Reg. No. 51,254 Leslie M. Hill, Reg. No. 51,805 Leslie L. Jacobs, 17, Reg. No. 40,659 David R. Marsh, Reg. No. 41,408 Joseph Micallef, Reg. No. 39,772 Lisa A. Penoyer, Reg. No. 51,204 Holly Logue Prutz, Reg. No. 47,755 Joseph W. Ricigliano, Reg. No. 48,511 Sidney A. Rosenzweig, Reg. No. 43,893 William Sekyi, Reg. No. 45,831 Ali R. Sharifahmadian, Reg. No. 48,202 Michael J. Songer, Reg. No. 39,841 Marcia Sundeen, Reg. No. 30,893 Millan M. Vinnola, Reg. No. 45,979 Todd A. Wagner, Reg. No. 35,399 Robert Jones Worrall, Reg. No. 37,969 Paul Zegger, Reg. No. 33,821,

all of Arnold & Porter, and

Molly A. Holman, Reg. No. 40,022

Joanna L. Moore, Reg. No. 44,950,

both of Amylin Pharmaceuticals, Inc.

Please address future correspondence to

ARNOLD & PORTER Attn: IP Docketing Department, Room 1126B 555 Twelfth Street, NW Washington, DC 20004-1206

Telephone calls should be directed to David R. Marsh, (202) 942-5000 and facsimile transmissions to (202) 942-5999.

FOR: Amylin Pharmaceuticals, Inc.

SIGNATU

Lloyd A. Rowland

TITLE: Vice President and General Counsel

DATE: 5/12

Amvlin 858-552-2212

Mar 17,2003 10:07AM PST >USPTO

Review of

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Young et al.
Appln. No.: 09/889,330
Exan

Art Unit: 1653

Filed: January 14, 2000

Examiner: Liu, 8.

riled: January 14

Atty. Docket: 030639.0027.UTL1

For: NOVEL EXENDIN

FORMULATIONS AND METHODS OF ADMINISTRATION

THEREOF

Revocation of Prior Power of Attorney, Appointment of New Attorneys of Record and Change of Correspondence Address

Commissioner for Patents Washington, D.C. 20231

Sir:

Amylin Pharmaceuticals, Inc. is the assignee of the entire right, title and interest in the above-identified application by virtue of the assignment recorded on December 27, 2001 at the U.S. Patent and Trademark Office at Reel 012474, Frame 0584, and the assignment recorded on May 6, 2002 at the U.S. Patent and Trademark Office at Reel 012878, Frame 0141. The undersigned, having express authority to represent Amylin Pharmaceuticals, Inc. as assignee, hereby revokes all powers of attorney heretofore given in the above-captioned application and appoints the attorneys and agents listed below with full power of substitution, association, and revocation, to prosecute said application and to transact all business in the U.S. Patent and Trademark Office connected therewith.